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The complement system, which contains some of the most potent pro-inflammatory mediators in the tissue including
the anaphylatoxins C3a and C5a are the vital parts of innate immunity. Complement activation seems to play a more
critical role in tumor development, but little attention has been given to the angiogenic balance of the activated
complement mediators and macrophage polarization during tumor progression. The tumor growth mainly supported
by the infiltration of M2- tumor-associated macrophages, and high levels of C3a and C5a, whereas M1-macrophages
contribute to immune-mediated tumor suppression. Macrophages express a cognate receptors for both C3a and C5a
on their cell surface, and specific binding of C3a and C5a affects the functional modulation and angiogenic properties.
Activation of complement mediators induce angiogenesis, favors an immunosuppressive microenvironment,
and activate cancer-associated signaling pathways to assist chronic inflammation. In this review manuscript, we
highlighted the specific roles of complement activation and macrophage polarization during uncontrolled
angiogenesis in tumor progression, and therefore blocking of complement mediators would be an alternative
therapeutic option for treating cancer.
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The complement system has been primarily considered
as an effector of innate immunity with the ability to
antibody-mediated disposal of foreign particles, apop-
totic clearance, and actively maintain the phase of im-
mune surveillance in different inflammatory states [1–4].
The complement activation play a dual role in tumor
development, and it has been reported that it can
control tumor activities through acute inflammation,
immunostimulation, lysis, opsonization and chemotaxis
[5]. In contrast, the complement activation also support
chronic inflammation, promote an immunosuppressive
microenvironment, induce angiogenesis, and activate
cancer-related signaling pathways during tumor progres-
sion [6]. Process of angiogenesis is firmly regulated by
the balance of two sets of counteracting mediators* Correspondence: mkhan26@kfshrc.edu.sa
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stage of 'angiogenic-switch' determines the time of initi-
ation of succeeding angiogenic phase and a physiological
up-regulation of angiogenic stimulators than angiogenic
inhibitors, as in the case of wound healing, which will
turn-on angiogenic switch to speed up the process of
normal angiogenesis [8, 9]. During the process of normal
angiogenesis, each step is tightly remained under the
control of different immune regulators but in some
pathological cases, the 'angiogenic-switch' remains in the
active state, which leads to uncontrolled angiogenesis in
many physiological disorders including tumor progres-
sion [10]. Malignant cells are able to maintain a balance
between complement activation and inhibition thereby
manipulates most advantages of complement initiation
without suffering its destructive effects [11, 12]. In this
perspective, inhibition or blocking of complement medi-
ators would be a potential therapeutic option for treating
cancer [12–14]. This review further highlights howcle distributed under the terms of the Creative Commons Attribution License
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protect their proliferation, and survival by recruiting
tumor-associated macrophages (TAMs) and facilitates
tumor progression.
A. How do tumor cell skip anti-tumor effects of
inflammation?
Tumor progression has a unique property, which
makes tumor cells to skip the anti-tumor effects of
inflammation in order to polarize immune responses
toward those effectors that facilitates tumor progression.
It has been reported that cancer cells adopt a variety of
cellular machineries to trick complement-mediated in-
jury [15]. The deleterious roles of complement mediators
on the eradication of tumors have not been investigated
in details. However, by virtue, complement has tendency
to recognize non-self-elements, and it is interesting to
note that any structural manipulations in the tumor cell
membranes make these cells an easy target for comple-
ment attack, and a number of clinical studies have re-
ported an activation of complement in cancer patients
[16, 17]. The activation of complement cascade release
key anaphylatoxins C5a and C3a, which are potent
chemo-attractants for macrophages, eosinophils, mono-
cytes, and T cells [18, 19] and modulate complement me-
diated tissue injury through the release of cytokines,
eicosanoids, and reactive oxygen species [18, 19]. To
protect from the complement, cancer cells develop aCance
cell
TAM (M
TAM (M2 like) 
TAM (M2 like) 






Fig. 1 Mechanism of cancer cell protection. Model illustrates the shielding
effector immune responses. It shows complement resistant cancer cells are
complement regulatory proteins (GREEN dots)variety of configurational strategies to combat complement-
mediated damage [15]. Due to these structural ma-
nipulations, though, malignant cells are recognized by
complement mediators but survive complement medi-
ated lysis through the shielding role of complement
regulatory proteins [20] (Fig. 1). This regulated com-
plement activation provides a permanent source of
complement mediators that could support the tumor
growth favorable inflammatory microenvironment [21, 22],
and it was shown in number of in-vitro cancer cell line
studies that the overproduction of complement activation
product C5a [5]. In addition, elevated levels of plasma C5a
has been reported in Lung cancer [5, 23], and in other tis-
sue specific cancers [23, 24]. Furthermore, It has been
found in number of cancer models that tumor inflamma-
tory microenvironment constitutes complement activated
fragments C3, C4, and C5, Clq, and MAC [12], high levels
of IL-6 [25] and TGF-β [26]. IL-6 has been shown to assist
tumor progression though apoptosis inhibition, angiogen-
esis stimulation [27].
B. Complement cascade mediators:
The complement cascade consists of plasma and
membrane-bound proteins, which protects against
immune-mediated tissue injury in different pathogenic
conditions [28]. Activation of complement cascade
initiated through three different pathways: the classical
pathway, the lectin pathway, and the alternative pathway.r
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mechanism orchestrated by cancer cells to protect against host
hugely infiltrated with C3a and C5a, TAMs and over-expressed
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pivotal complement molecule C3 and generate C3 conver-
tase [29]. This C3 convertase promotes the cleavage of C3
into C3a and C3b. After cleavage of C3, C3b molecule
combines with the C3 convertase to form C4bC2aC3b
complex in classical and lectin pathways, and to the for-
mation of C3bBbC3b complex in the alternative pathway.
Both C4bC2aC3b and C3bBbC3b complexes are known as
C5 convertase and cleaves C5 into C5a and C5b mole-
cules. The generated C5a can then function as a potent
anaphylatoxin at the site of production while C5b partici-
pates in the assembly of the membrane attack complex
(C5b-9 or MAC) [29]. Finally, MAC complex can initiate
cell lysis, and in sublytic quantities can lead to cell activa-
tion (Fig. 2). The main sources of C3 in human are hepa-
tocytes [30], but C3 is also expressed by macrophages
[31], fibroblasts [32], vascular endothelium [33], astroglia
[34] and adipocytes [35]. Beside of involvement in comple-
ment activation, C3 and its degradation products are able
to promote phagocytosis, activate inflammatory responses
against pathogens, and regulate adaptive immune, but un-
controlled activation may result in host cell damage [36].
The complement cascade plays a vital role in antimicrobial
defense and the clearance of immune complexes and
apoptotic cells [37]. This latter property is a recognized












Fig. 2 Macrophage polarization: Model illustrates M1 and M2 macrophage
promote tumor growth through the release of TGF-β, IL-10, IL-17, IL-23, VEG
suppress tumor growth through the release IFN-γ IL-12, and TNF-αinflammatory diseases, including rheumatoid arthritis,
glomerulonephritis, atherosclerosis, asthma, and mul-
tiple sclerosis [38]. Substantial research has proven the
evidence of the activated complement mediators in cellu-
lar proliferation, and diseases of chronic inflammation,
which suggest a potentially deleterious role in abnormal
cellular growth [18, 39]. Thus, it is not overwhelming
that signals for complement-mediated disease patho-
genesis has centered mainly on the dysfunctional im-
munity caused by the absence, alteration, or over
activation of complement proteins [39]. It has been re-
ported that complement proteins mediate cellular turn-
over, growth, and regeneration, including bone marrow
stem cell engraftment, bone and cartilage development,
neurogenesis, synaptogenesis, white matter healing, and
regeneration of the liver, limb, and lens [12, 40, 41].
C. Macrophages during tumor progression:
Macrophages are an important component of the in-
nate immune system, they are characterized by the ex-
pression of number of unique surface markers including
CD14, CD11b, CD11c, F4/80, MAC-1/MAC-3, CD163,
and CD68 [42, 43]. It has been found in number of
tumor models that macrophages support cancer cells







mediated angiogenesis in tumor development. M2 macrophages
F, and FGF2 required for tumor growth. In contrast, M1 macrophages
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stop apoptosis, and promote cell proliferation [45–47].
Macrophages maintain essentials of tissue remodeling,
inflammation, and immunity, include endocytosis of for-
eign and necrotic debris, cytotoxicity, and secretion of
more than different cytokines [48–50]. However, de-
pending on their activation, macrophages are able to se-
crete growth factors, prostaglandins, interferon, elastase,
plasminogen activator, and collagenase, and complement
components C3 and C5 [51]. Macrophages have classic-
ally activated M1 and alternatively activated M2 sub-
types, and the differentiation in to respective subtype is
mediated through the release of cytokines and growth
factors present in the inflammatory microenvironment
[52–54]. The development of M1 macrophages stimu-
lated through IFN-γ and TNF-α [55], whereas, the M2
macrophages are polarized by IL-4, IL-13 [54]. As men-
tioned, the immunological effects of both M1 and M2
subtypes are regulated through the myriad of cytokines.
It has been reported that IFN-γ stimulated M1 macro-
phages elevate the production of IL-12 and IL-23, and
low IL-10 [50, 56]. However, M2 macrophages favor over
production of IL-10 and low levels of IL-12 and IL-23
[56, 57]. M1 macrophage secreted IL-12 promotes the
differentiation of Th1 cells, which can improve antigen
phagocytosis [48], while IL-23 triggers the Th17 cells
proliferation and release of IL-17, which modulates in-
flammatory autoimmune pathologies [58, 59]. On the
other side, the M2 macrophage secreted IL-10 favor theMacrophage
M1




Fig. 3 Regulation of angiogenesis. Model illustrates macrophage-mediated
regulate the phase of angiogenesis under normal physiological conditionsproduction of IL-4 and IL-13 by Th2 cells [60]. The M1
macrophage derived chemokines are also critical for kill-
ing intercellular pathogens, whereas the M2 macrophage
derived chemokines promote the recruitment of the leu-
kocytes involved in tissue repair and remodeling process
[54]. It has been reported that macrophage polarization
occurs during onset of tumor progression and it changes
from classically activated M1 to alternatively activated
M2 like Tumor-Associated Macrophages (TAMs) [54].
Depending on the physiological and pathological condi-
tions, macrophages undergo differentiation into M1 and
M2 phenotypes and both play a key role in maintaining
tumor growth [61]. M1 macrophages are pro-inflammatory
in function, they secrete IFN-γ, IL-12 and TNF-α, and
therefore effectively suppress tumor growth [62, 63]
while M2 like TAMs secrete TGF-β, IL-10, IL-17, IL-23,
VEGF, and FGF2 [62], promote angiogenesis and tumor
progression (Fig. 3). M2 TAMs produce VEGF, FGF
chemokines IL-17, IL-23, or TGF-β that contribute to
stimulation of vascular endothelial cell proliferation, re-
lease of MMPs, which degrade the vascular basement
membrane and induce sprouting, migration of endothe-
lial cells into the tumor and this process further leads to
tube formation and maturation of new microvessel.
[62]. M2 TAMs promotes the proliferation of tumor
cells directly by secreting growth factors, and partici-
pate in tumor progression by acting on endothelial cells,
and thus promoting the neovascularization of the tumor
[49, 62, 64]. M2 TAMs are the key player duringTumor progression
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regulation of angiogenesis: This explains how complement mediators
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cascade [56, 65, 66]. The angiogenic phenotype of mac-
rophages is in part defined by their ability to secrete
molecules that promote or inhibit angiogenesis [54, 56,
65–67]. During tumor progression, M2 TAMs are mi-
grated to tumors under the influence of various cyto-
kines and growth factors secreted by cancer and stromal
cells. However, it has been shown that M1 macrophages
express IFN-γ, IL-1, and IL-6, which prime T-cell to-
wards anti-tumor type-1 inflammatory response [68].
However, in most tumors such as breast, prostate, ovar-
ian, cervical, lung carcinoma, and cutaneous melanoma,
M2 TAMs are considered to be anti-inflammatory and
correlated with a poor prognosis [56, 69]. M2 TAMs
mostly occupy hypoxic regions of tumors, and express
more proangiogenic genes, such as VEGF, pFGF,
CXCL8, and glycolytic enzymes, through the transcrip-
tion factors HIF-1α and HIF-2 [70, 71]. Most TAMs dis-
play M2 associated molecules, which includes IL-10 and
MGL1, as well as CCL2, CCL5, CXCL9, CXCL10, and
CXCL16, and heat shock proteins [72, 73]. In addition,
the tumor microenvironment, which includes IL-4,
IL-13, TGF-β, and IL-10 further support the adoption of
an M2 phenotype [54]. M2 TAMs are associated with
different stages of tumor development, which includes
tumor progression, angiogenesis, uncontrolled growth,
actual metastasis, immunosuppression, matrix depos-
ition, and tissue remodeling [56, 74]. It has been re-
ported that M2 TAMs are able to modulate and induce
neovascularization and support functions. In addition,
activated TAMs release growth factors (VEGF and
PDGF), cytokines (TGF-β), proteases, and chemokines,
which promote angiogenesis in many tumors, such as
gliomas, squamous cell carcinomas of the esophagus,
and breast, bladder, and prostate carcinomas [56, 65].
Moreover, TAM-secreted matrix metalloproteases (MMP-
1, MMP-2, MMP-3, MMP-9, and MMP-12), and plasmin
are also support angiogenesis [75]. In addition, MMP-9
support angiogenesis through the release of VEGF sig-
naling [76]. TAMs preferentially accumulate in hypoxic
and necrotic regions within the tumors and become
M2-angiogenic [62].
D. Complement activation during angiogenesis and in
tumor progression:
The complement regulates both innate and adaptive
immune systems, and more particularly during the phase
of acute inflammation, complement anaphylatoxins C3a
and C5a mediates changes in microvascular flow, perme-
ability, leukocyte extravasation and migration, which
contributes to tissue damage after ischemia reperfusion
and in other disease models [2, 77]. The active comple-
ment proteins, C3a and C5a, control macrophagemediated angiogenesis in tissue [12, 40, 41]. C3a and
C5a generated from complement cascade have potential
effects on macrophage-mediated angiogenesis inhibition.
Both C3a and C5a anaphylatoxins bind to their respect-
ive C3aR and C5aR on monocytes/macrophages [78]
and many other cells including airway epithelium, caus-
ing an anti-angiogenic response resulted in an increased
IL-6, TNF-α, sVEGFR1, and decreased IL-10 mRNA. In-
creased sVEGFR1 secretion from monocytes/macro-
phages inhibits angiogenesis in different disease models
[40, 41] (Fig. 2). It has been well established in trans-
plants model that C3−/− recipients mice exhibited more
dilated and leaky microvessels as compare to the control
allografts [2, 77]. In addition, the latest research outcomes
in mouse model of retinopathy reveals the importance of
complement in regulating increased neovascularization in
C3−/− mice compared with control groups [79]. Along
with C3 role in neovascularization, C5a also play a crucial
role in angiogenesis, and increased neovascularization was
observed in C5aR−/− mice compared with control group
[79]. C5aR antagonist supported the process of neo-
vascularization, whereas treatment with C5a agonist
reduced neovascularization in retinopathy model, con-
firming the inhibitory role of C5a and C5aR in this
process [79]. Moreover, treatment of C3−/− with C3a
and C5a reduced the enhanced neovascularization effect
observed in C3−/− mice, suggesting that C3a and C5a
are inhibitory effectors of pathologic hypoxia-driven
retinal neovascularization [79].
Complement proteins have been reported to facilitate
tumor progression through the dysregulation of mito-
genic signaling pathways, continuous cellular prolifera-
tion, angiogenesis, insensitivity to apoptosis, invasion
and migration, and escape from immunosurveillance
[12, 14, 80]. During the phase of tumor progression,
complement anaphylatoxins C3a and C5a increase mito-
genic signaling pathways. The cell inducing abilities of
the C3a and C5a have been reported [81] and also re-
vealed the involvement in several other signal trans-
duction pathways with known links to neoplastic
progression (Fig. 3). In addition, complement receptors
(C3aR1) and (C5aR1) are coupled to G-proteins and
mostly present in M2 macrophages, airway epithelium,
and parenchymal vessels. Number of research findings
have shown that the membrane attack complex, which is
one of the main terminal product of complement cas-
cade, also activates the cell cycle and oncogenic path-
ways [82, 83]. It is well known and established that
under hypoxic conditions, progression from a small
population of neoplastic cells to a clinically significant
mass requires creation of new microvessels to perfuse
the newly formed malignant tissue structure [84]. More-
over, number of studies has revealed that the extent of
tumor vessels formation suggested a direct link between
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predict the growth rate and progression of the disease
[85]. Activation of complement cascade has been exam-
ined through in-vitro studies of cancer cell lines and I
was found that Lung cancer cells are able to produce
C5a more efficiently than do non-malignant bronchial
epithelial cells but the mechanism is still not yet ex-
plained [5]. The classical pathway has been recognized
as the major contributor to complement activation on
subcutaneously inoculated TC-1 cervical cancer cells
[13] and in two neuroblastoma cell lines in vitro [17]. In
the case of primary tumors, Lucas et al. [86] have re-
ported that a tumor-specific immune activation occurs
in papillary thyroid carcinomas, with activation of the
classical pathway. In addition, role of classical pathway
has also been reported in follicular, MALT lymphomas
[87], and in patients with chronic lymphocytic leukemia
[88]. In contrast, the results of other studies has demon-
strated that lymphoma and myeloma cells activate the
alternative pathway of the complement cascade [89].
Furthermore, both the alternative and the classical cas-
cade has also been reported in some cases [90, 91], while
the lectin pathway has been found to be significantly ac-
tivated in colorectal cancer patients. The immuno regu-
latory functions of C3a and C5a and their receptors (CR)
has been characterized in cancer models, and it was
found that number of myeloid-derived innate immune
cells express C3aR and C5aR, including monocytes,
macrophages, DCs, neutrophils, basophils, T cells, mast
cells, and eosinophils [92–94]. Through, its influence on
innate immune cells including DCs and macrophages,
C3a similarly regulates the T cell response, especially the
determination of Th1 cells [14].
Conclusions
The complement system help innate immune attack
against cancer cells through cytotoxic and lytic effects
but number of studies are revealing that the comple-
ment cascade enables a remarkable array of proliferative
events [20]. Both complement and macrophages interact
closely to maintain process of angiogenesis, and modu-
late the major features of carcinogenesis, including dys-
regulation of mitogenic signaling pathways, sustained
cellular proliferation, angiogenesis, and insensitivity to
apoptosis, invasion, metastasis, and escape from immuno-
surveillance. Macrophages also tune inflammation and
adaptive immunity, promote cell proliferation by release
of number of growth factors, ornithine, and polyamines.
They also take active role in promoting angiogenesis, tis-
sue remodeling, and tissue repair [66, 95, 96]. M2 macro-
phages acts as a tumor promoters at distinct phases of
malignant progression of gastric, mammary [97], lung
[98], and liver carcinomas [99]. Macrophages express re-
ceptors for activated C3 and C5, respond to activated C3aand C5a mediators at the site of local inflammation, and
maintain angiogenesis in tissue [79]. There are significant
research evidences, which support the contribution of
complement activation to tumor progression [22, 24, 100].
During tumor progression, tumor cells undergo genetic
and epigenetic manipulations that modulate their malig-
nant growth [5, 101, 102]. Due to these manipulations, the
complement system can differentiate and recognize tumor
cells from non-malignant cells [29, 103, 104], which pro-
tect cancer cells from deleterious effects of complement
mediators [105]. It has been demonstrated in mouse
model of cervical cancer that the generation of C5a in the
tumor microenvironment promotes tumor progression
through the recruitment of myeloid-derived suppressor
cells and the generation of an immunosuppressive micro-
environment [106]. However, in lung carcinogenesis
model, C5a play a key role as a mediator in the regulation
of cancer growth [5], and targeted inhibition of the C5a
bindings to its receptors could inhibit the microenvi-
ronment without diminishing the protective effects of
complement activation [107]. In addition to its anti-
inflammatory role, complement play a crucial role in sev-
eral transduction pathways involved in tumor progression.
C5a is a key regulator of complement mediated inflamma-
tory response during tumor progression [18]. The thera-
peutic blockade of the complement system to suppress
tumor progression has been investigated by antagonizing
the C5aR receptor [13], and it was suggested that tumor
cells evade lysis by the use of protective mechanism
that limits the formation of functional MAC pores
[108]. In addition, It has been demonstrated that MAC
activates cancer-associated signaling pathways through
MAPK, phosphatidylinositol 3-kinase, Ras, and p70 S6
kinase [82, 109, 110], and inhibit apoptosis cancer cells
by blocking FLIP, caspase-8 [111].
These findings reflects that cancer cells utilize comple-
ment modulation as a shield to protect itself from sur-
rounding effector molecules, and thereby favors tumor
progression. This unique adoptability of cancer cells un-
cover the key importance of targeted complement inhib-
ition to restrict tumor growth [105, 112]. A number of
studies are targeting the potential role for complement-
mediated therapeutics options to rescue tissue from tumor
progression. There is particular interest in the applications
of monoclonal antibodies against the soluble and
membrane-bound complement inhibitors reported by
different tumors, an approach believed to enhance
antitumor complement-dependent cytotoxicity and
antibody-dependent cell-mediated cytotoxicity. How-
ever, the increasingly interest of complement inter-
action with tumor cells demands further information,
and suggest possibility that anti-complement strategies
[2, 77] may offer an entirely new means of fighting
number of complement mediated diseases including
Khan et al. Journal of Biomedical Science  (2015) 22:58 Page 7 of 9cancer and tumor progressions. This review uncover
the cross-talk between complement proteins and mac-
rophages on tumor progression and future of comple-
ment as a potential therapeutic target to rescue tissue
from tumor progression.
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